Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cognition Therapeutics will present in vitro results on the role of sigma-2 receptors and the effect of their drug candidate CT1812 on dry age-related macular degeneration (AMD) at the upcoming ARVO meeting in New Orleans from April 23-27.
CT1812, an orally delivered small molecule, targets sigma-2 receptors and shows potential in modulating biological pathways affected by dry AMD, including immune response and cell survival. The detailed findings will be showcased in poster #C0072 during the conference.
The company is also preparing for a Phase 2 clinical trial of CT1812 for geographic atrophy linked to dry AMD, with clinical site selection currently underway. The drug is under investigation for mild-to-moderate Alzheimer's disease and dementia with Lewy bodies as well.
Cognition Therapeutics announced the publication of a review article in the International Journal of Molecular Sciences discussing the mechanistic rationale for sigma-2 receptor modulation in age-related degenerative diseases including Alzheimer's disease and dementia with Lewy bodies. The article highlights the role of the sigma-2 receptor in neuronal function and its potential as a therapeutic target. Cognition's lead compound, CT1812, aims to advance to Phase 2 clinical trials. The study focuses on restoring synaptic health by targeting cellular processes impaired by neurodegenerative diseases. Cognition’s strategy underscores the unique mechanism of CT1812 in addressing significant unmet medical needs in neurodegeneration.
On March 28, 2023, Cognition Therapeutics (NASDAQ: CGTX) disclosed findings from a meta-analysis involving 24 participants in the Phase 2 SHINE-A study and data from the Phase 1b SPARC study. The results indicate that treatment with CT1812 yields statistically significant effects on key Alzheimer's disease markers, notably improving synapse health and reducing neuroinflammation. Notable changes in cerebrospinal fluid levels of clusterin and prion protein were observed, underscoring CT1812's potential in altering disease processes. These results were presented at the AD/PD™ 2023 conference, enhancing understanding of CT1812's therapeutic effects.
Cognition Therapeutics (Nasdaq: CGTX) has released its fourth video podcast discussing dementia with Lewy bodies (DLB), featuring insights from four neuroscience experts. The podcast highlights the overlap between DLB, Alzheimer’s, and Parkinson’s diseases, including symptoms, clinical features, and the importance of accurate diagnosis. Currently, there are no approved disease-modifying treatments for DLB, which affects about 1.4 million Americans. The company is conducting the Phase 2 SHIMMER study for its lead candidate, CT1812, with a $30M grant from the NIH’s National Institute on Aging to evaluate treatment effects on DLB.
Cognition Therapeutics, Inc. (Nasdaq: CGTX) has announced significant progress in its clinical development, including the completion of enrollment in the Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease. The company received FDA clearance for the Phase 2 START study and the IND for a Phase 2 study targeting geographic atrophy due to dry AMD. Financially, the company secured an equity commitment of up to $35 million and raised $6 million through a public offering, with cash reserves expected to fund operations into the second half of 2024. However, Cognition reported a net loss of $21.4 million for 2022, reflecting increased R&D and G&A expenses.